After participating in this educational activity, attendees should be able to:
1. Explain the details of planning and launching the COVID-19 Monoclonal Antibody (mAb) Treatment Program
2. Discuss the strategies employed in this multifaceted treatment program
3. Describe the lessons learned in operations from the COVID-19 mAb treatment program
4. Describe an incident command structure relative to disaster preparedness (in this case, a pandemic)
5. Describe how initiatives are rapidly implemented and evolved to accommodate the imperatives related to a disaster
Armando Paez, M.D.
Chief, Director, Infectious Disease Fellowship Program
Division of Infectious Diseases
Chief Operating Officer, Baystate Medical Practices
Vice President, BH Ambulatory Operations
The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Faculty or planner conflicts of interest are resolved before the educational activity.
None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients. Dr. Paez will discuss off-label/investigative uses of the following commercial products: Bamlanivimab, casirivimab, and imdevimab, which are COVID-19 monoclonal antibodies authorized (not fully approved yet) by the FDA, and which will be mentioned as part of the clinical program. These are still considered investigative agents.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC Contact Hours
- 1.00 BCIPE Instructional Hours